Diadema Partners LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 2026172) · Explore on the interactive board
Diadema Partners LP disclosed 78 US equity positions worth $283.2m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is UTHR at 10.1% of the reported book, followed by RVMD, ABVX. The top ten holdings are 62.5% of the book, and the portfolio behaves like about 21 equal-weight positions. Versus the prior filing it opened 29 new positions, added to 21, reduced 19 and exited 24. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Diadema Partners LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 29 new, 21 added, 19 reduced, 24 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 10.1% | $28.7m | 52,989 | 94% | added |
| 2 | RVMD REVOLUTION MEDICINES INC | Healthcare | 9.2% | $26.1m | 139,218 | 72% | added |
| 3 | ABVX ABIVAX SA | Healthcare | 7.6% | $21.6m | 163,644 | 115% | added |
| 4 | COGT COGENT BIOSCIENCES INC | Healthcare | 6.7% | $19.1m | 493,664 | 53% | added |
| 5 | BRIDGEBIO PHARMA INC | 6.6% | $18.6m | 250,000 | 0% | held | |
| 6 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 6.3% | $17.9m | 312,846 | 111% | added |
| 7 | VKTX VIKING THERAPEUTICS INC | Healthcare | 6.1% | $17.2m | 441,808 | -16% | reduced |
| 8 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 3.9% | $11.1m | 272,214 | – | new |
| 9 | KOD KODIAK SCIENCES INC | Healthcare | 3.0% | $8.5m | 218,117 | 13% | added |
| 10 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 2.9% | $8.1m | 254,863 | 32% | added |
| 11 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 2.7% | $7.6m | 571,107 | – | new |
| 12 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 2.4% | $6.9m | 223,810 | -6% | reduced |
| 13 | JNJ JOHNSON & JOHNSON | Healthcare | 2.0% | $5.6m | 22,000 | -59% | reduced |
| 14 | NVO NOVO-NORDISK A S | Healthcare | 1.7% | $4.8m | 100,000 | 586% | added |
| 15 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 1.6% | $4.4m | 294,811 | 20% | added |
| 16 | RLAY RELAY THERAPEUTICS INC | Healthcare | 1.5% | $4.3m | 230,677 | – | new |
| 17 | ZYME ZYMEWORKS INC | Healthcare | 1.3% | $3.7m | 142,132 | 0% | held |
| 18 | BIOA BIOAGE LABS INC | 1.3% | $3.6m | 146,334 | 144% | added | |
| 19 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.3% | $3.6m | 522,619 | – | new |
| 20 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.0% | $2.9m | 121,539 | – | new |
| 21 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 1.0% | $2.8m | 301,264 | -32% | reduced |
| 22 | INDV INDIVIOR PHARMACEUTICALS INC | Healthcare | 1.0% | $2.8m | 67,512 | -5% | reduced |
| 23 | IVA INVENTIVA SA | 1.0% | $2.7m | 740,786 | 110% | added | |
| 24 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.9% | $2.6m | 27,799 | – | new |
| 25 | PCVX VAXCYTE INC | Healthcare | 0.9% | $2.6m | 45,071 | 80% | added |
| 26 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 0.9% | $2.5m | 361,367 | 80% | added |
| 27 | VERA VERA THERAPEUTICS INC | Healthcare | 0.9% | $2.5m | 57,608 | – | new |
| 28 | CTNM CONTINEUM THERAPEUTICS INC | 0.7% | $2.0m | 119,733 | – | new | |
| 29 | BCYC BICYCLE THERAPEUTICS PLC | Healthcare | 0.7% | $2.0m | 462,724 | -3% | reduced |
| 30 | GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 0.7% | $1.9m | 78,391 | -58% | reduced |
| 31 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.6% | $1.8m | 100,000 | – | new |
| 32 | MGNX MACROGENICS INC | Healthcare | 0.6% | $1.7m | 374,403 | -38% | reduced |
| 33 | PROQR THRAPEUTICS N V | 0.6% | $1.7m | 926,016 | 414% | added | |
| 34 | SPRB SPRUCE BIOSCIENCES INC | 0.6% | $1.6m | 30,000 | 200% | added | |
| 35 | ARDX ARDELYX INC | Healthcare | 0.5% | $1.5m | 303,025 | – | new |
| 36 | CUE CUE BIOPHARMA INC | 0.5% | $1.5m | 48,369 | – | new | |
| 37 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 0.5% | $1.5m | 56,347 | 114% | added |
| 38 | PRTA PROTHENA CORP PLC | Healthcare | 0.5% | $1.5m | 149,482 | – | new |
| 39 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 0.5% | $1.4m | 413,642 | -2% | reduced |
| 40 | UNCY UNICYCIVE THERAPEUTICS INC | 0.5% | $1.4m | 303,676 | 186% | added | |
| 41 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 0.5% | $1.4m | 129,950 | 138% | added |
| 42 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 0.5% | $1.3m | 15,000 | – | new |
| 43 | HELP CYBIN INC | 0.5% | $1.3m | 200,000 | – | new | |
| 44 | EQ EQUILLIUM INC | 0.5% | $1.3m | 400,282 | -8% | reduced | |
| 45 | XERS XERIS BIOPHARMA HOLDINGS INC | Healthcare | 0.4% | $1.1m | 132,746 | 0% | held |
| 46 | PHVS PHARVARIS N V | Healthcare | 0.4% | $1.0m | 29,321 | 0% | held |
| 47 | HRMY HARMONY BIOSCIENCES HLDGS IN | Healthcare | 0.3% | $978.1k | 26,864 | -71% | reduced |
| 48 | RNAC CARTESIAN THERAPEUTICS INC | 0.3% | $907.1k | 87,057 | – | new | |
| 49 | RIGL RIGEL PHARMACEUTICALS INC | 0.3% | $892.6k | 22,816 | – | new | |
| 50 | SMMT SUMMIT THERAPEUTICS INC | Healthcare | 0.3% | $874.2k | 60,000 | – | new |
What did Diadema Partners LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| JAZZ JAZZ PHARMACEUTICALS PLC | 21.2% | $10.4m |
| 430 TERNS PHARMACEUTICALS INC | 19.6% | $9.6m |
| BBIO BRIDGEBIO PHARMA INC | 13.0% | $6.3m |
| ABBV ABBVIE INC | 10.7% | $5.2m |
| GPCR STRUCTURE THERAPEUTICS INC | 7.1% | $3.5m |
| CLYM CLIMB BIO INC | 4.0% | $2.0m |
| STTK SHATTUCK LABS INC | 3.9% | $1.9m |
| TARS TARSUS PHARMACEUTICALS INC | 3.7% | $1.8m |
| ALKS ALKERMES PLC | 3.6% | $1.8m |
| VRTX VERTEX PHARMACEUTICALS INC | 3.5% | $1.7m |
| DNTH DIANTHUS THERAPEUTICS INC | 1.7% | $839.2k |
| ENTA ENANTA PHARMACEUTICALS INC | 1.7% | $820.3k |
| RARE ULTRAGENYX PHARMACEUTICAL IN | 1.5% | $736.3k |
| MAZE MAZE THERAPEUTICS INC | 0.9% | $447.8k |
| LPCN LIPOCINE INC NEW | 0.8% | $399.5k |
| GHRS GH RESEARCH PLC | 0.8% | $377.3k |
| EPRX EUPRAXIA PHARMACEUTICALS INC | 0.6% | $289.6k |
| TRVI TREVI THERAPEUTICS INC | 0.5% | $258.4k |
| CMPS COMPASS PATHWAYS PLC | 0.4% | $176.3k |
| PASG PASSAGE BIO INC | 0.3% | $153.3k |
| RCKT ROCKET PHARMACEUTICALS INC | 0.2% | $109.5k |
| RNA ATRIUM THERAPEUTICS INC | 0.1% | $33.6k |
| CUE CUE BIOPHARMA INC | 0.1% | $30.3k |
| PURETECH HEALTH PLC | 0.0% | $11.3k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 85.7% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Diadema Partners LP's portfolio?
Across every quarter Diadema Partners LP has filed, its median largest position is 8.9% of the book and its median top-ten weight is 56.4%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 36.0 completed holding spells, the median lasted 1.0 quarters; 78.0 positions are still open and their final length is unknown.